Key Differences Between 2017 and 2026 ATA Guidelines on Thyroid Disorders in Pregnancy
The 2026 ATA guidelines represent a substantial evolution from the 2017 version, incorporating new evidence on subclinical hypothyroidism management, expanding the multidisciplinary approach with 10 international societies and patient advocacy groups, and utilizing the more rigorous GRADE framework instead of the American College of Physicians system. 1, 2
Major Methodological Advances
Evidence Evaluation Framework
- 2017 Guidelines: Used the American College of Physicians Guideline Grading System for evidence appraisal 2
- 2026 Guidelines: Adopted the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) framework, which provides more standardized and internationally recognized methodology for assessing evidence quality and formulating recommendations 1
Stakeholder Involvement
- 2017 Guidelines: Task force had limited representation, primarily from endocrinology and obstetrics 2
- 2026 Guidelines: Dramatically expanded to include representatives from 10 international societies, patient advocacy groups, and a dedicated methodologist, reflecting a more comprehensive, patient-centered approach 1
Clinical Scope Expansion
Preconception Care
- 2017 Guidelines: Addressed preconception considerations but with less emphasis 2
- 2026 Guidelines: Explicitly expanded to include dedicated preconception recommendations as a distinct phase, recognizing the importance of optimizing thyroid function before pregnancy 1
Disease Coverage
Both guidelines address:
- Thyroid function testing interpretation
- Iodine supplementation
- Thyroid autoimmunity
- Hypothyroidism and hypothyroxinemia
- Hyperthyroidism and Graves' disease
- Thyroid nodules and cancer
- Postpartum thyroid dysfunction
However, the 2026 version provides more granular recommendations with enhanced focus on equity and feasibility considerations 1, 2
Subclinical Hypothyroidism Management Evolution
Treatment Thresholds - A Critical Change
The most clinically significant evolution concerns TPO antibody-negative subclinical hypothyroidism:
2017 Approach: Recommended to "consider treatment" for TPO antibody-negative pregnant women with TSH between the upper limit of normal and 10.0 mIU/L, creating ambiguity in clinical practice 2, 3
Post-2017 Evidence: Multiple studies published between 2017-2026 demonstrated that treating TPO antibody-negative women diagnosed with subclinical hypothyroidism in the second trimester or later does not improve outcomes 4. However, moderate-quality evidence emerged supporting treatment of TPO antibody-negative women with elevated TSH in the first trimester 4, 5
2026 Refinement: While the exact wording awaits full guideline publication, the 2026 guidelines incorporate this new evidence, likely providing more definitive guidance on timing and antibody status considerations 1
TSH Reference Range Refinement
Both guidelines moved away from the rigid 2.5 mIU/L cutoff that characterized earlier recommendations, but the 2026 version benefits from additional years of data on pregnancy-specific reference ranges 1, 2, 3
The 2017 guidelines already acknowledged that treating all women with TSH 2.5-4.0 mIU/L who are TPO antibody-negative was likely unnecessary, reducing overtreatment 3. The 2026 guidelines further refine these thresholds based on accumulated evidence.
Practical Implementation Differences
Good Practice Statements
- 2026 Guidelines: Introduced "Good Practice Statements" for areas where formal evidence is limited but expert consensus exists, providing clearer guidance in evidence gaps 1
- 2017 Guidelines: Did not utilize this specific framework 2
Equity and Feasibility Considerations
- 2026 Guidelines: Explicitly incorporated equity and feasibility into recommendation formulation, recognizing global disparities in access to thyroid testing and treatment 1
- 2017 Guidelines: Less explicit focus on these implementation factors 2
Hyperthyroidism Management
Antithyroid Drug Selection
Both guidelines maintain the core principle established in 2011 guidelines [6-6]:
- First trimester: Propylthiouracil (PTU) preferred due to methimazole teratogenicity concerns
- Second/third trimesters: Switch to methimazole due to PTU hepatotoxicity risk
The 2026 guidelines likely provide updated safety data and more nuanced guidance on the timing of switches between medications 1
Thyroid Autoimmunity and Assisted Reproduction
A significant evidence-based change emerged between 2017-2026: Research published after 2017 demonstrated that treating euthyroid, TPO antibody-positive women undergoing assisted reproductive technology does not improve outcomes 4
The 2026 guidelines incorporate this evidence, likely recommending against routine treatment in this population 1, 4
Postpartum Thyroid Dysfunction
Both guidelines address postpartum thyroiditis, but the 2026 version benefits from additional longitudinal data on:
- Natural history of postpartum thyroid dysfunction
- Risk stratification for permanent hypothyroidism
- Optimal monitoring intervals
Thyroid Nodules and Cancer in Pregnancy
The 2026 guidelines align with the separate 2025 ATA guidelines on differentiated thyroid cancer 7, providing more contemporary recommendations on:
- Risk stratification during pregnancy
- Timing of interventions
- Postpartum management strategies
Iodine Nutrition
Both guidelines emphasize adequate iodine intake, but the 2026 version likely provides:
- Updated global data on iodine sufficiency
- More specific recommendations for different populations
- Clearer guidance on supplementation in iodine-sufficient regions
Screening Recommendations
Both the 2017 and 2026 guidelines maintain opposition to universal screening, instead recommending targeted, case-finding approaches for high-risk women 1, 2, 8. This consensus persists despite ongoing debate in the field.
Quality of Evidence Acknowledgment
A notable feature of the 2026 guidelines is explicit acknowledgment that much evidence remains low-to-moderate quality, while still providing "current best practices and consensus among international experts" 1. This transparency helps clinicians understand the limitations of recommendations while still providing actionable guidance.
Common Pitfalls to Avoid
Overtreatment Based on Outdated Thresholds
Do not automatically treat all pregnant women with TSH >2.5 mIU/L. Use pregnancy-specific reference ranges and consider antibody status and trimester of diagnosis.
Misapplication of Antibody-Negative Recommendations
The evidence against treating TPO antibody-negative subclinical hypothyroidism applies primarily to second/third trimester diagnosis. First trimester diagnosis may warrant different management.
Switching Antithyroid Drugs Too Frequently
While the PTU-to-methimazole switch is recommended, excessive back-and-forth changes can destabilize thyroid control. Plan transitions carefully at trimester boundaries.
Ignoring Equity Considerations
The 2026 guidelines emphasize that recommendations must be adapted to local resources and access to care, particularly in resource-limited settings.